## Abstract ## BACKGROUND: In 2007, the US Food and Drug Administration (FDA) issued regulatory alerts for use of erythropoiesisโstimulating agents (ESAs) in cancer patients with anemia after clinical trials and metaโanalysis data found that high ESA doses were associated with adverse outcomes in
Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer
โ Scribed by Scott Klarenbach; Braden Manns; Tony Reiman; Martin Neil Reaume; Helen Lee; Anita Lloyd; Natasha Wiebe; Brenda Hemmelgarn; Marcello Tonelli
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 269 KB
- Volume
- 116
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract Safety concerns surrounding the use of recombinant human erythropoietin (Epo) to treat anemia in cancer patients were raised after 2 recent clinical studies reported a worse survival outcome in patients who received epoetin ฮฑ or epoetin ฮฒ compared with patients who received placebo. Alt
## Abstract In the economic evaluation of health care programmes, productivity costs are often estimated using patients' wages for the period of absence. However, the use of such methods for short periods of absence is controversial. A previous study found that shortโterm absence is often compensat
## Abstract ## BACKGROUND. It has been shown that nonpharmacologic interventions are effective management techniques for cancerโrelated fatigue (CRF) in cancer survivors. However, few studies have investigated their effectiveness in patients who are receiving chemotherapy. In this study, the autho
## Abstract We evaluated the associations of such lifestyle factors as alcohol drinking, coffee consumption and medical history with risk of death from pancreatic cancer in a largeโscale prospective cohort study [the Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC study)] in Ja